Researchers find clues to SARS-CoV-2 infection and explore why COVID-19 impacts patients differently

Findings suggest there must be other other receptors for the virus that regulate infection of the lungs
11-Aug-2020 8:40 AM EDT, by McMaster University

 

Newswise — Hamilton, ON (August 11, 2020) – Working together, researchers at McMaster University and the University of Waterloo are searching for how the SARS-CoV-2 virus infects the lungs – and they’re challenging what has become an accepted truth about the virus.

Previously, scientists have determined that entry of SARS-CoV-2 into cells occurs through a receptor on the cell surface, known as ACE2. But the McMaster-Waterloo team has found that the ACE2 receptor is at very low levels in human lung tissue.

“Our finding is somewhat controversial, as it suggests that there must be other ways, other receptors for the virus, that regulate its infection of the lungs,” said Jeremy Hirota, co-lead scientist of the team from the Research Institute of St. Joe’s Hamilton and an Assistant Professor of Medicine at McMaster.

“We were surprised that the fundamental characterization of the candidate receptors in human lung tissue had not yet been done in a systematic way with modern technologies.”

“Finding such low levels of ACE2 in lung tissue has important implications for how we think about this virus.” said co-lead Andrew Doxey, Professor of Biology at the University of Waterloo. “ACE2 is not the full story and may be more relevant in other tissues such as the vascular system.”

A paper on their findings has been published recently in the European Respiratory Journal. Their findings have been confirmed independently by other researchers in Molecular Systems Biology

Now, to explore alternate additional infection pathways and different patient responses to infection, the team is using nasal swabs that were collected for clinical diagnoses of COVID-19. These samples offer the opportunity to determine which genes are expressed by patients’ cells and associate this information with the development of the patients’ disease.

The ongoing study will better identify and treat patients who are at risk of developing serious complications and provide predictive capacity for hospitals.

“It is clear that some individuals respond better than others to the same SARS-CoV-2 virus.  The differential response to the same virus suggests that each individual patient, with their unique characteristics, heavily influences COVID-19 disease severity,” said Hirota, who holds the Canada Research Chair in Respiratory Mucosal Immunology at McMaster.  

“We think it is the lung immune system that differs between COVID-19 patients, and by understanding which patients’ lung immune systems are helpful and which are harmful, we may be able to help physicians pro-actively manage the most at risk-patients.”

Researchers will correlate positive and negative COVID-19 cases with clinical outcomes, and ultimately use this data to generate predictive algorithms related to morbidity and mortality. The aim is to use this predictive information to optimize health care delivery.

The research has received grants from the Ontario COVID-19 Rapid Research Fund of the Ontario government, from the COVID-19 Innovation Challenge of Roche Canada and from FastGrants.org managed by the Thistledown Foundation in Canada.

“We’re looking for additional partners to collaborate with us in moving this research forward, as we believe there is an opportunity to develop diagnostic devices with this information,” said Hirota.

 

-30-

 

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5419
Released: 15-Apr-2021 4:10 PM EDT
Penn Study Suggests Those Who Had COVID-19 May Only Need One Vaccine Dose
Perelman School of Medicine at the University of Pennsylvania

New findings from Penn suggest that people who have recovered from COVID-19 may only need a single mRNA vaccine dose. However, those who did not have COVID-19 did not have a full immune response until after a second vaccine dose, reinforcing the importance of completing the two recommended doses.

Released: 15-Apr-2021 4:00 PM EDT
June 2021 Issue of AJPH Comprises the Effects of COVID-19 on Drug Overdoses, E-cigarette Use, and Public Health Measures and Strategies
American Public Health Association (APHA)

June 2021 AJPH Issue highlights COVID-19 concerns in relation to fatal drug overdoses, drops in youth e-cigarette use, importance of public health measures, and strategies to protect correctional staff.

Newswise: 262150_web.jpg
Released: 15-Apr-2021 3:20 PM EDT
COVID-19 reduces access to opioid dependency treatment for new patients
Princeton University

COVID-19 has been associated with increases in opioid overdose deaths, which may be in part because the pandemic limited access to buprenorphine, a treatment used for opioid dependency, according to a new study led by Princeton University researchers.

Newswise: UGA to Establish National NIH-funded Center to Fight Flu
Released: 15-Apr-2021 2:45 PM EDT
UGA to Establish National NIH-funded Center to Fight Flu
University of Georgia

The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research (CIDER). The contract will provide $1 million in first-year funding and is expected to be supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, for seven years and up to approximately $92 million.

Released: 15-Apr-2021 2:15 PM EDT
Meatpacking plants increased COVID-19 cases in US counties
University of California, Davis

An estimated 334,000 COVID-19 cases are attributable to meatpacking plants, resulting in $11.2 billion in economic damage, according to a new study led by a researcher at the University of California, Davis.

Newswise: 262052_web.jpg
Released: 15-Apr-2021 1:55 PM EDT
How to build a city that prioritizes public health
Colorado State University

Most people by now have memorized the public health guidelines meant to help minimize transmission of COVID-19: wash your hands, wear a mask, keep six feet apart from others. That part is easy.

Released: 15-Apr-2021 1:45 PM EDT
Wake Forest School of Medicine Begins Study to Test New Mask for Healthcare Workers
Wake Forest Baptist Health

Open Standard Industries, Inc. (OSI), manufacturer of the OSR-M1 non-valved reusable elastomeric face mask, is pleased to formally announce the launch of its first Institutional Review Board (IRB)-approved user feasibility study. The trial is being led by the departments of Biomedical Engineering and Infectious Diseases at Wake Forest School of Medicine, part of Wake Forest Baptist Health. Recruitment in the study is underway, and enrollment is expected to be completed by May 28, 2021.

Newswise: Major clinical trial to test Pfizer-BioNTech COVID-19 vaccine opens for enrollment at UTHealth in Houston
Released: 15-Apr-2021 1:45 PM EDT
Major clinical trial to test Pfizer-BioNTech COVID-19 vaccine opens for enrollment at UTHealth in Houston
University of Texas Health Science Center at Houston

A large national clinical trial to evaluate the Pfizer-BioNTech COVID-19 vaccine for safety and efficacy in pregnant women is now open for enrollment at The University of Texas Health Science Center at Houston (UTHealth).

Released: 15-Apr-2021 1:15 PM EDT
For veterans, a hidden side effect of COVID: Feelings of personal growth
Yale University

The U.S. military veteran population is known to have abnormally high rates of suicide, so health officials have been concerned that the COVID-19 pandemic might elevate risk of psychiatric disorders, particularly among those suffering from post-traumatic stress and related disorders.

Newswise: 262026_web.jpg
Released: 15-Apr-2021 12:55 PM EDT
Significant spread of all coronavirus variants tracked in Houston area
Elsevier

In late 2020, several concerning SARS-CoV-2 variants emerged globally. They are believed to be more easily transmissible, and there is concern that some may reduce the effectiveness of antibody treatments and vaccines.


Showing results

110 of 5419

close
2.02487